Endothelial Facilitation in Alzheimer's Disease. An Open Label Pilot Study of the Sequential and Cumulative Effects of Simvastatin, L-Arginine, and Sapropterin (Kuvan) on Cerebral Blood Flow and Cognitive Function in Patients With Alzheimer's Disease

Trial Profile

Endothelial Facilitation in Alzheimer's Disease. An Open Label Pilot Study of the Sequential and Cumulative Effects of Simvastatin, L-Arginine, and Sapropterin (Kuvan) on Cerebral Blood Flow and Cognitive Function in Patients With Alzheimer's Disease

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Mar 2018

At a glance

  • Drugs Arginine (Primary) ; Sapropterin (Primary) ; Simvastatin (Primary)
  • Indications Alzheimer's disease
  • Focus Pharmacodynamics
  • Most Recent Events

    • 05 Mar 2018 Status changed from active, no longer recruiting to completed.
    • 06 Jan 2017 Status changed from recruiting to active, no longer recruiting.
    • 04 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top